NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. - Wikidata - wikimedia - TriplyDB

NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.

NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.

http://www.wikidata.org/entity/Q36399548

about

NKG2D ligands as therapeutic targets Role of cancer microenvironment in metastasis: focus on colon cancer Metastasis: a question of life or death CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors Transience in polarization of cytolytic effectors is required for efficient killing and controlled by Cdc42 Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation.IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis.Genetics, genomics, and evolutionary biology of NKG2D ligands.Perforin: more than just a pore-forming protein.Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1.NKG2D function protects the host from tumor initiation.Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.Trial watch: Prognostic and predictive value of the immune infiltrate in cancer Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies Sustained CTL activation by murine pulmonary epithelial cells promotes the development of COPD-like disease.NK cells and cancer immunosurveillance.NKG2D ligands in tumor immunity.NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline Murine NKG2D ligands: "double, double toil and trouble".MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells.Proteasome regulation of ULBP1 transcription.Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer.Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27.Natural killer cells and solid tumors.Targeting NKG2D in tumor surveillance.The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.Shaping of NK cell responses by the tumor microenvironment Dynamics of NK cell interactions in vivo.γδ T cells as a potential tool in colon cancer immunotherapy.Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.Type I Interferons and Natural Killer Cell Regulation in Cancer.Evaluation of a flow cytometry-based assay for natural killer cell activity in clinical settings.

P2860

Q27014888-3DE1130D-5293-4CB4-BD74-4180743C89E6 Q28239062-2FF30846-66BD-4065-ADD5-A5D9841501AB Q28242176-A486A7FA-7F02-485C-A030-0776371A5648 Q30442426-6664EE8C-60D1-419E-8D9C-03AC6A2C3DDA Q30495371-11FEEF28-3BBF-4CCA-9930-3C79AE841ECF Q33815894-EE05F219-8E33-493F-83F7-5419462CB0E3 Q33917198-56546BEC-0E21-4BDC-99CF-1B0EAD1BBBF4 Q33929197-2B8CB0E7-5ED6-41DE-B0B6-75FB8BDF7AF2 Q34489980-B52693E5-73BF-40DF-98E8-4167A0ABBEA7 Q34616180-494AADA9-8394-4D82-A8C0-030EE3BA5CA9 Q35709263-72CBF698-D12E-4C8E-A9DB-7F96E92D0C78 Q35751039-E1FDA67A-7D72-4638-8139-093695E3BA03 Q35794137-11FC9384-04AD-492A-B762-D701177596DF Q36402828-69D876E0-40AF-458B-84CC-2F2B2E721AAA Q36403058-39AB0025-35B9-48C9-843E-27D886EABCA5 Q36403637-FCBD7F79-7C9C-4E1F-AC01-49FB1DEB17F9 Q36456483-58677F17-8C30-454B-AAA4-E307AB302143 Q36605917-7CFF7E86-1D56-4BE5-9EF9-34D257DA3845 Q36810264-F4AB867E-44C2-43B2-B07A-547610F421C9 Q36969858-AE78C094-4B70-472A-9799-A8FC2B208EEC Q37047061-660E51AD-4CA5-41A0-B12D-888CD83B47B1 Q37111384-F64E1E14-891E-4079-A4EE-15D8B4EF69B4 Q37287176-B047AF2C-66E4-49C8-93C5-607F6DE42802 Q37287179-F9F47A26-3018-40B8-9D89-F5D33E99F9C0 Q37316220-55FA49BE-3E42-4A41-B217-6EA281F64579 Q37350455-FC699819-F30C-439F-920A-06E21E03DD96 Q37357114-20F075CF-5C4D-4030-926D-F4C68F646B32 Q37357720-245BC6FF-1119-4DC4-8B1E-8E10679511FC Q37370451-4C43D41D-0352-4C1C-A711-8224A7999942 Q37439660-AA997D4D-D6B8-4C63-B372-E9C88E9EA8DC Q37592689-44129ACF-36D3-4EFD-B03D-BFC620366891 Q37866598-0E6FCB33-F6AE-4F5A-A9E4-72C7782D2B17 Q38005176-7336B27E-6AC0-4EEE-B03A-D05652453416 Q38021845-72567268-B692-4D35-B08D-16A6E4BF8B14 Q38067641-43F7AEE8-9F72-4A31-B8BE-B18B946F8BE8 Q38070791-2D02F6ED-4981-47EE-B970-597A470BD941 Q38262257-9EABBB5D-79FF-4265-92EB-0BF415A6038A Q38849985-0B31A32E-20CC-46B0-B92E-A86B388AEEBC Q39241784-BF508F28-0341-4E7A-8730-1EA4672AD323 Q39431665-CB0603CA-4A41-4661-AA6B-EB6A984D0B93

P2860

NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.

http://www.wikidata.org/entity/Q36399548

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

NKG2D recognition and perforin ...... okine immunotherapy of cancer.

@ast

NKG2D recognition and perforin ...... okine immunotherapy of cancer.

@en

type

label

NKG2D recognition and perforin ...... okine immunotherapy of cancer.

@ast

NKG2D recognition and perforin ...... okine immunotherapy of cancer.

@en

prefLabel

NKG2D recognition and perforin ...... okine immunotherapy of cancer.

@ast

NKG2D recognition and perforin ...... okine immunotherapy of cancer.

@en

P1433

Q36399548-AECE7479-3BCF-431E-B796-263EFC284C48

P1476

Q36399548-908FE0AC-3D11-48A1-A2F7-E4094FB16B83

P2093

Q36399548-0678FCDD-F9D7-4861-A978-F40C07464BB0

Q36399548-091461AC-8A50-4130-8111-5223EC23E57D

Q36399548-7F8E1CA6-4F06-4559-8141-475D463079A8

Q36399548-ACA011EC-81B1-49AE-9E50-A25400C24060

Q36399548-CE984713-44A1-4931-B630-4714F43C5D56

Q36399548-DA8F0DDC-E2D8-47B3-9025-4816D64D7444

Q36399548-F89FAC14-0E02-4CA6-95BA-2BE573246E58

P2860

Q36399548-0B47C314-735B-4941-8202-D39337EF50D8

Q36399548-180B32D0-5527-4291-BE05-38C65742FA85

Q36399548-1871D4C6-51DF-4876-9329-B79AED42311C

Q36399548-2ADDBCED-95F9-4642-A5B3-8BD582331B08

Q36399548-38529782-C8C2-47A3-A362-FDEE60D6D029

Q36399548-3C7ABDC9-E55E-486C-B198-E2FCF6EB72AA

Q36399548-3DDA7D15-3B4A-4ABD-8FB5-DCD9093E194D

Q36399548-4E3B2DEA-C8F1-457D-A571-46AE6AD7CB48

Q36399548-51B8B767-1E23-40D8-85B1-B1DA38C2B1BB

Q36399548-54904970-AD3F-42AE-B623-CFA87B829E5D

P304

Q36399548-9980B795-2289-4F8F-A2F9-A03E4A68F02F

P31

Q36399548-85C624CF-D16A-4367-9758-24323A26897E

P356

Q36399548-B202C63B-ABB3-4372-B87E-C3A8532FB8BB

P407

Q36399548-99B6FA92-1F88-4285-B034-465537C90E1F

P433

Q36399548-3D9DE102-5540-4BF1-AEE1-BA480237769A

P478

Q36399548-A899998B-7696-4266-9E9B-B86C7E2CA036

P50

Q36399548-4F14AF69-9E37-446E-8923-DF48EFDF66E6

P577

Q36399548-FBD52A47-010C-4385-91E9-8BE273B19C75

P5875

Q36399548-4E01FD7B-B758-4DF1-852A-72E4C4B2981F

P698

Q36399548-D61451FF-E8DF-41A6-9E70-7835DEF16070

P921

Q36399548-10551AD3-DC08-41B2-96F2-5590C9288020

P932

Q36399548-69AD3613-5273-4198-8BF8-258A72FF910C

P356

P1433

Journal of Experimental Medicine

P1476

NKG2D recognition and perforin ...... okine immunotherapy of cancer.

@en

P2093

Andreas Diefenbach

http://www.w3.org/2001/XMLSchema#string

Erika Cretney

http://www.w3.org/2001/XMLSchema#string

Janice M Kelly

http://www.w3.org/2001/XMLSchema#string

Jeremy Swann

http://www.w3.org/2001/XMLSchema#string

Thomas J Sayers

http://www.w3.org/2001/XMLSchema#string

Wayne M Yokoyama

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Hayakawa

http://www.w3.org/2001/XMLSchema#string

P2860

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells

ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor

Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA

DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells

Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity

Innate immune recognition

Regulation of cutaneous malignancy by gammadelta T cells

NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation

P304

1325-1335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20041522

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

200

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8182370

http://www.w3.org/2001/XMLSchema#string

P698

15545356

http://www.w3.org/2001/XMLSchema#string

P921

P932

2211920

http://www.w3.org/2001/XMLSchema#string